Given the lack of WRN inhibitor response data in cancer patients harbouring KMT2DWT and KMT2DLOF tumours, the lack of a relationship between KMT2D status and WRN inhibitors in patient samples (e.g. biopsies) remains a limitation of our study. This evidence concerns the gene WRN and neoplasm.